The global cytomegalovirus treatment market size was estimated to be USD 467.9 million in 2023 and is expected to reach at USD 997.0 million by 2034 with a CAGR of 7.12% during the forecast period 2024-2034. The growing incidence of CMV infection, heightened awareness about CMV infection, a heightened emphasis on advancing more efficacious treatments for CMV, an increased prevalence of chronic diseases, a rising inclination towards personalized medicine, greater accessibility of CMV treatments, augmented initiatives to raise awareness about treatments and diagnosis, an upsurge in clinical trial studies for novel drug development, an increased prevalence of viral infections in AIDS patients due to compromised immune systems, and a growing number of regulatory approvals for novel cytomegalovirus treatment options are some of the key factors boosting the market growth.
A growing number of regulatory approvals for novel cytomegalovirus treatment options is predicted to boost the market growth during the forecast period. Cytomegalovirus (CMV) infection, a common herpesvirus ailment, exhibits a range of symptoms from none to fever, fatigue, and severe manifestations impacting internal organs, eyes, and the brain. CMV is a communicable condition transmissible through blood, semen, saliva, urine, and breast milk. Antiviral medications represent the primary treatment approach, effectively slowing down virus replication but not halting it. Commercially accessible antiviral drugs for cytomegalovirus treatment include ganciclovir, foscarnet, valganciclovir, cidofovir, among others. For instance, in May 2022, Hologic, Inc. reported that the FDA in the United States has granted approval for its Aptima CMV Quant assay, which measures the viral load of Cytomegalovirus (CMV) in individuals who have undergone solid organ or stem cell transplants.
By drug type, Ganciclovir was the highest revenue-grossing segment in the global cytomegalovirus treatment market in 2023 owing to the widely employed as an antiviral medication for the treatment and prevention of infections, ganciclovir has witnessed a surge in research and development activities. Notably, it stands out as the most effective drug, yielding rapid and effective results. Additionally, Valganciclovir is predicted to grow at the fastest CAGR during the forecast period. Valganciclovir is characterized by its simplicity and convenience, providing the potential for enhanced patient compliance. There is an increasing emphasis on the development of novel drugs in this context. For instance, in February 2023, Merck, also recognized as MSD internationally (excluding the United States and Canada), declared that the U.S. Food and Drug Administration (FDA) has agreed to assess two supplemental new drug applications (sNDA) for PREVYMIS (letermovir).
By application, stem cell transplantation was the highest revenue-grossing segment in the global cytomegalovirus treatment market in 2023 owing to the increasing influx of funds from both government and private entities to support clinical trials for stem cell therapy, the implementation of comprehensive guidelines for the manufacturing of stem cell therapy is on the rise, various regulatory authorities are granting approvals for these products. For instance, in September 2022, Health Canada has granted authorization (Notice of Compliance) for Takeda's LIVTENCITY (maribavir) to be used in treating adults with post-transplant cytomegalovirus (CMV) infection or disease. This authorization extends to individuals who are refractory (with or without genotypic resistance) to one or more previous antiviral therapies and those who have undergone a solid organ transplant or a hematopoietic stem cell transplant. Additionally, organ transplantation is predicted to grow at the fastest CAGR during the forecast period owing to the individuals undergoing organ transplantation face an increased risk of CMV infection. The use of immunosuppressive therapy to prevent organ rejection in transplant recipients heightens their vulnerability to CMV reactivation. Effectively addressing CMV in this patient group is essential to prevent complications and enhance transplant outcomes, resulting in a growing demand for CMV treatment within the realm of organ transplantation.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global cytomegalovirus treatment market in 2023. Hospitals play a crucial role in providing specialized care to patients, particularly those with compromised immune systems or undergoing organ transplantation. The presence of a range of CMV drugs and antiviral therapies in hospital pharmacies ensures the prompt and suitable treatment of patients. With their capacity to navigate the intricacies of managing CMV infections across diverse patient groups, hospital pharmacies emerge as central hubs for CMV treatment. The collaborative dynamics among healthcare teams within hospitals further streamline communication and coordination for the effective management of CMV cases. Additionally, retail pharmacy is predicted to grow at the fastest CAGR during the forecast period owing to the ready accessibility and availability of diverse drugs, a notable increase in the count of retail pharmacy stores, and growing financial support from major market players. For instance, in June 2022, Synklino successfully concluded a Series A funding round, securing EUR 29.8 million (USD 31.8 million). The company is focused on the development of drugs for addressing chronic viral infections, and the raised funds will be directed towards advancing its drug candidate, SYN002, specifically designed for treating cytomegalovirus (CMV).
North America region is anticipated for the highest revenue share during the forecast period owing to the growing occurrences of cytomegalovirus infections, the notable increase in the availability of treatments for CMV, and the rising number of product approvals are contributing to the provision of safe and effective treatments for patients. For instance, in September 2022, ProBioGen and City of Hope, a U.S.-based cancer research and treatment institution, have entered a non-exclusive commercial license agreement. Under this agreement, City of Hope is granted the ability to manufacture its innovative synthetic MVA-based CMV vaccine using ProBioGen's scalable viral manufacturing platform, AGE1.CR.pIX. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness of the disease among consumers, an increased demand for effective treatment, a growing preference for personalized medicine, and an uptick in approvals by regulatory bodies. For instance, in December 2023, Takeda has revealed that Maribavir received approval from the National Medical Products Administration (NMPA) in China for treating adult patients with cytomegalovirus (CMV) infection/disease following hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). This approval is specifically for cases refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.
A growing number of regulatory approvals for novel cytomegalovirus treatment options is predicted to boost the market growth during the forecast period. Cytomegalovirus (CMV) infection, a common herpesvirus ailment, exhibits a range of symptoms from none to fever, fatigue, and severe manifestations impacting internal organs, eyes, and the brain. CMV is a communicable condition transmissible through blood, semen, saliva, urine, and breast milk. Antiviral medications represent the primary treatment approach, effectively slowing down virus replication but not halting it. Commercially accessible antiviral drugs for cytomegalovirus treatment include ganciclovir, foscarnet, valganciclovir, cidofovir, among others. For instance, in May 2022, Hologic, Inc. reported that the FDA in the United States has granted approval for its Aptima CMV Quant assay, which measures the viral load of Cytomegalovirus (CMV) in individuals who have undergone solid organ or stem cell transplants.
By drug type, Ganciclovir was the highest revenue-grossing segment in the global cytomegalovirus treatment market in 2023 owing to the widely employed as an antiviral medication for the treatment and prevention of infections, ganciclovir has witnessed a surge in research and development activities. Notably, it stands out as the most effective drug, yielding rapid and effective results. Additionally, Valganciclovir is predicted to grow at the fastest CAGR during the forecast period. Valganciclovir is characterized by its simplicity and convenience, providing the potential for enhanced patient compliance. There is an increasing emphasis on the development of novel drugs in this context. For instance, in February 2023, Merck, also recognized as MSD internationally (excluding the United States and Canada), declared that the U.S. Food and Drug Administration (FDA) has agreed to assess two supplemental new drug applications (sNDA) for PREVYMIS (letermovir).
By application, stem cell transplantation was the highest revenue-grossing segment in the global cytomegalovirus treatment market in 2023 owing to the increasing influx of funds from both government and private entities to support clinical trials for stem cell therapy, the implementation of comprehensive guidelines for the manufacturing of stem cell therapy is on the rise, various regulatory authorities are granting approvals for these products. For instance, in September 2022, Health Canada has granted authorization (Notice of Compliance) for Takeda's LIVTENCITY (maribavir) to be used in treating adults with post-transplant cytomegalovirus (CMV) infection or disease. This authorization extends to individuals who are refractory (with or without genotypic resistance) to one or more previous antiviral therapies and those who have undergone a solid organ transplant or a hematopoietic stem cell transplant. Additionally, organ transplantation is predicted to grow at the fastest CAGR during the forecast period owing to the individuals undergoing organ transplantation face an increased risk of CMV infection. The use of immunosuppressive therapy to prevent organ rejection in transplant recipients heightens their vulnerability to CMV reactivation. Effectively addressing CMV in this patient group is essential to prevent complications and enhance transplant outcomes, resulting in a growing demand for CMV treatment within the realm of organ transplantation.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global cytomegalovirus treatment market in 2023. Hospitals play a crucial role in providing specialized care to patients, particularly those with compromised immune systems or undergoing organ transplantation. The presence of a range of CMV drugs and antiviral therapies in hospital pharmacies ensures the prompt and suitable treatment of patients. With their capacity to navigate the intricacies of managing CMV infections across diverse patient groups, hospital pharmacies emerge as central hubs for CMV treatment. The collaborative dynamics among healthcare teams within hospitals further streamline communication and coordination for the effective management of CMV cases. Additionally, retail pharmacy is predicted to grow at the fastest CAGR during the forecast period owing to the ready accessibility and availability of diverse drugs, a notable increase in the count of retail pharmacy stores, and growing financial support from major market players. For instance, in June 2022, Synklino successfully concluded a Series A funding round, securing EUR 29.8 million (USD 31.8 million). The company is focused on the development of drugs for addressing chronic viral infections, and the raised funds will be directed towards advancing its drug candidate, SYN002, specifically designed for treating cytomegalovirus (CMV).
North America region is anticipated for the highest revenue share during the forecast period owing to the growing occurrences of cytomegalovirus infections, the notable increase in the availability of treatments for CMV, and the rising number of product approvals are contributing to the provision of safe and effective treatments for patients. For instance, in September 2022, ProBioGen and City of Hope, a U.S.-based cancer research and treatment institution, have entered a non-exclusive commercial license agreement. Under this agreement, City of Hope is granted the ability to manufacture its innovative synthetic MVA-based CMV vaccine using ProBioGen's scalable viral manufacturing platform, AGE1.CR.pIX. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness of the disease among consumers, an increased demand for effective treatment, a growing preference for personalized medicine, and an uptick in approvals by regulatory bodies. For instance, in December 2023, Takeda has revealed that Maribavir received approval from the National Medical Products Administration (NMPA) in China for treating adult patients with cytomegalovirus (CMV) infection/disease following hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). This approval is specifically for cases refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.
Segmentation: Cytomegalovirus Treatment Market Report 2023 - 2034
Cytomegalovirus Treatment Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Mn)
- Valganciclovir
- Foscarnet
- Ganciclovir
- Cidofovir
Cytomegalovirus Treatment Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Congenital CMV Infection
- Organ Transplantation
- Stem Cell Transplantation
- Other
Cytomegalovirus Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce
Cytomegalovirus Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cytomegalovirus Treatment Market: Drug Type Estimates & Trend Analysis
8. Cytomegalovirus Treatment Market: Application Estimates & Trend Analysis
9. Cytomegalovirus Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cytomegalovirus Treatment Market
12. Europe Global Cytomegalovirus Treatment Market
13. Asia Pacific Global Cytomegalovirus Treatment Market
14. Latin America Global Cytomegalovirus Treatment Market
15. MEA Global Cytomegalovirus Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Clinigen Group PLC
- Gilead Sciences
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc
- Teva Pharmaceuticals Inc
- Mylan N.V
- Genentech Inc.
- Thermo Fisher Scientific
- Chimerix
- Takeda Pharmaceuticals
- Pfizer
- Fresenius Kabi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 467.9 Million |
| Forecasted Market Value ( USD | $ 997 Million |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
